Phase I Study in Patients With Solid Tumours

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol. Patients entered into the dose escalation phase will not be entered into the expansion phase. All subjects must be suitable for treatment with either carboplatin and/or paclitaxel.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel; Saracatinib

Criteria

Inclusion Criteria:

• Life expectancy > 12 weeks

• Women defined as post-menopausal

• Male or female patients with locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel

Exclusion Criteria:

• Inadequate bone marrow reserve

• Inadequate live function, renal function or low haemoglobin

• Unresolved toxicity from anti-cancer therapy